Background: Real-life data often highlight the side effects of certain drugs not previously reported in randomized controlled trials (RCTs).Objective: To describe cutaneous inflammatory eruptions in psoriatic patients treated with an anti IL-17A agent (secukinumab or ixekizumab).Methods: Retrospective analysis of a cohort of patients with chronic plaque psoriasis who started an anti IL-17A agent between September 2016-February 2019 and who developed cutaneous inflammatory eruptions during treatment. A systematic review of similar events reported in the literature was performed.Results: Data of 468 patients were reviewed and 27 cutaneous inflammatory eruptions of 27 (5.8%) patients were collected. The eruptions appeared after a mean of 16.9 ± 17.0 weeks of therapy showing a classical acute eczema in 11 patients (40.7%), an atopic dermatitis-like rash in 11 patients (40.7%) and a psoriasiform eruption in 5 patients (18.5%). Histopathology of 12/27 cases showed epidermal spongiosis in all these variants.Conclusion: We described the clinic-pathologic features of some eczematous eruptions occurring in psoriatic patients, 3-4 months after treatment initiation with an anti IL-17A agent. Further investigations are needed to explain this phenomenon, that might be defined a paradoxical adverse event, based upon the role of IL17 in eczema pathogenesis.

Caldarola, G., Pirro, F., Di Stefani, A., Talamonti, M., Galluzzo, M., D'Adamio, S., et al. (2020). Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. EXPERT OPINION ON BIOLOGICAL THERAPY, 20(6), 665-672 [10.1080/14712598.2020.1727439].

Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature

Talamonti, M;Galluzzo, M;Bianchi, L;
2020-01-01

Abstract

Background: Real-life data often highlight the side effects of certain drugs not previously reported in randomized controlled trials (RCTs).Objective: To describe cutaneous inflammatory eruptions in psoriatic patients treated with an anti IL-17A agent (secukinumab or ixekizumab).Methods: Retrospective analysis of a cohort of patients with chronic plaque psoriasis who started an anti IL-17A agent between September 2016-February 2019 and who developed cutaneous inflammatory eruptions during treatment. A systematic review of similar events reported in the literature was performed.Results: Data of 468 patients were reviewed and 27 cutaneous inflammatory eruptions of 27 (5.8%) patients were collected. The eruptions appeared after a mean of 16.9 ± 17.0 weeks of therapy showing a classical acute eczema in 11 patients (40.7%), an atopic dermatitis-like rash in 11 patients (40.7%) and a psoriasiform eruption in 5 patients (18.5%). Histopathology of 12/27 cases showed epidermal spongiosis in all these variants.Conclusion: We described the clinic-pathologic features of some eczematous eruptions occurring in psoriatic patients, 3-4 months after treatment initiation with an anti IL-17A agent. Further investigations are needed to explain this phenomenon, that might be defined a paradoxical adverse event, based upon the role of IL17 in eczema pathogenesis.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35
English
IL17; Psoriasis; anti IL17; eczematous reactions; ixekizumab; secukinumab; side effects
Caldarola, G., Pirro, F., Di Stefani, A., Talamonti, M., Galluzzo, M., D'Adamio, S., et al. (2020). Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. EXPERT OPINION ON BIOLOGICAL THERAPY, 20(6), 665-672 [10.1080/14712598.2020.1727439].
Caldarola, G; Pirro, F; Di Stefani, A; Talamonti, M; Galluzzo, M; D'Adamio, S; Magnano, M; Bernardini, N; Malagoli, P; Bardazzi, F; Potenza, C; Bianchi, L; Peris, K; De Simone, C
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
caldarola.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 7.08 MB
Formato Adobe PDF
7.08 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/230862
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 36
social impact